Andrew R Simpson

US Patent:

20040142413, Jul 22, 2004

Filed:

Aug 25, 2003

Appl. No.:

10/297465

Inventors:

Andrew Simpson - New York NY, US
Fernando Reinach - Sao Paulo, BR
Joao Setubal - Campina, BR
Joao Meidanis - Campinas, BR
Paulo Arruda - Campinas, BR

International Classification:

C07H021/04
C12N001/21
C07K014/195

US Classification:

435/069100, 435/252300, 435/320100, 530/350000, 536/023700

Abstract:

The complete genome has been isolated and sequenced. The complete sequence can be placed on various computer readable media, and used diagnostically.

US Patent:

20130237475, Sep 12, 2013

Filed:

Sep 13, 2011

Appl. No.:

13/824378

Inventors:

Miriam Tendler - Rio de Janeiro, BR
Celso Raul Romero Ramos - Rio de Janeiro, BR
Andrew J.G. Simpson - New York NY, US

Assignee:

ALVOS - CONSULTORIA, DESENVOLVIMENTO E COMERCIALIZAÇÃO DE PRODUTOS BIOTECNOLÓGICOS S/A - Rio de Janeiro
FUNDAÇÃO OSWALDO CRUZ - Rio de Janeiro

International Classification:

C07K 14/435

US Classification:

514 46, 536 235, 435 691, 530416, 436501

Abstract:

The present invention pertains to the field of production of recombinant proteins, using a synthetic gene for increased expression of the protein in . More specifically, the invention describes the production of a recombinant Sm14 protein of , by providing a synthetic gene for increased production of Sm14 protein, producing said gene and genetically manipulating the strain with said gene in order to produce a vaccine effectively. Improved methods are also provided for producing and purifying this protein from cells, which can be scaled for industrial production.

US Patent:

20200010515, Jan 9, 2020

Filed:

Jan 22, 2018

Appl. No.:

16/478521

Inventors:

- Manguinhos, Rio de Janeiro, BR
Andrew J.G. SIMPSON - New York NY, US
Celso Raul Romero RAMOS - Rio de Janeiro, BR

International Classification:

C07K 14/435
C12N 15/81
A61K 39/00

Abstract:

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in . More specifically, the invention describes the production of Sm14 recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from cells, which can be escalated for their industrial production, were also improved.

US Patent:

20160052963, Feb 25, 2016

Filed:

Oct 19, 2015

Appl. No.:

14/886794

Inventors:

- Rio de Janeiro, BR
Andrew J.G. SIMPSON - New York NY, US

International Classification:

C07K 1/36
C07K 14/435
C07K 14/395

Abstract:

A process for purification of a fatty acid binding proteins such as, e.g., Sm14 of or type-3 FABP protein of . The process includes the steps of: (a) performing lysis of cells containing the fatty acid binding protein to obtain a lysate; (b) clarifying the lysate obtained in step (a) to obtain a clarified lysate; (c) loading the clarified lysate in a column containing an anion exchange resin; (d) eluting proteins from the column by pH changes in the column; and (e) separating contaminant proteins from the fatty acid binding protein by gel-filtration.

US Patent:

20110177079, Jul 21, 2011

Filed:

Sep 8, 2005

Appl. No.:

11/662322

Inventors:

Yao-Tseng Chen - New York NY, US
Lloyd J. Old - New York NY, US
Andrew J.G. Simpson - New York NY, US
Victor C. Jongeneel - Lausanne, CH
Matthew J. Scanlan - , US
Cynthia H. Scanlan - , US

Assignee:

Ludwig Institute for Cancer Research - New York NY
Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 39/395
A61K 39/00
C07K 14/435
G01N 33/574
C12N 15/12
A61P 35/00

US Classification:

4241391, 4241851, 4241781, 530350, 530324, 436 64, 436501, 536 235

Abstract:

The invention relates to cancer-testis antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of novel cancer-testis (CT) antigens.